Physician profile
Riley E Greene
NPI 1326194945
$26,535.90
in general payments reported to CMS, 2019-2025
46 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,639 · 2020: $2,237 · 2021: $2,865 · 2022: $2,343 · 2023: $1,890 · 2024: $12K · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,000 · Food and Beverage: $5,394 · Consulting Fee: $2,620 · Travel and Lodging: $807 · Education: $370 · Honoraria: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,000.00 |
| Food and Beverage | $5,394.04 |
| Consulting Fee | $2,620.00 |
| Travel and Lodging | $807.41 |
| Education | $369.52 |
| Honoraria | $260.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $8,564.29 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Amgen INC. | $3,560.48 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $1,675.05 | 2019-2025 | Winlevi, Ilumya, Blu-U |
| Janssen Biotech, INC. | $1,561.49 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,268.61 | 2019-2025 | |
| Epi Health, LLC | $900.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $704.09 | 2019-2025 | |
| Ucb, INC. | $643.64 | 2019-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $642.21 | 2019-2025 | Jublia, Cabtreo |
| Lilly USA, LLC | $629.93 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $619.83 | 2019-2022 | |
| Incyte Corporation | $597.04 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $539.05 | 2021-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $529.75 | 2019-2025 | Libtayo |
| Pfizer INC. | $522.83 | 2019-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riley Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.